Posters

Early effect of anti-glaucoma treatment on central corneal thickness

Poster Details

First Author: Z.Kapsala GREECE

Co Author(s):    G. Bontzos   D. Pagoulatos                 

Abstract Details

Purpose:

To assess the early effect of topical latanoprost (50 μg/ml) and tafluprost (15 μg/ml) eye drops on central corneal thickness (CCT) in patients with primary open angle glaucoma (POAG).

Setting:

Ippokratio General Hospital of Athens, Athens, Greece.

Methods:

Totally, 58 eyes of 58 subjects were included in this prospective study enrolled in three different groups. Subjects with corneal degeneration, corneal scarring or history of ocular surgery and contact lens use were excluded from the study. Group 1 included 20 eyes with POAG under latanoprost (50 μg/ml) eyes drops. Group 2 included 20 eyes with POAG under tafluprost (15 μg/ml) eyes drops. Group 3 served as control and consisted of 18 eyes not receiving any topical anti-glaucoma treatment. CCT was assessed at 3 time points; at month 0, 3 and 6 after the initiation of anti-glaucoma therapy.

Results:

Mean age of the study groups mentioned above was 64.3±16.1, 66.9±12.8 and 71.1±16.4 years old, respectively. In groups 1 and 2, a mild gradual decrease of mean CCT was observed during the 6-month interval, but the differences detected were not statistically significant. No obvious change of CCT was recorded in the control group.

Conclusions:

Latanoprost (50 μg/ml) and tafluprost (15 μg/ml) eye drops seem to cause a mild decrease of CCT after a 6-month instillation. Further longitudinal prospective studies are necessary to clarify the incidence of any early effects of these topical prostaglandin analogues on CCT.

Financial Disclosure:

None